I am a surgeon-scientist focused on developing targeted nanotherapeutic drug delivery systems for the upper airway to improve clinical outcomes in adults with chronic rhinosinusitis (CRS). During my otolaryngology residency, and, more recently, during a 2-year research focused fellowship at the University of Utah, I gained significant experience in patient-centered outcomes research within the field of CRS. I published over 40 papers focusing on CRS, and presented my findings nationally at biannual conferences over the last 3 years. During fellowship, I became acutely aware of the lack of innovation in medical management of CRS in the last 20 years. In part due to a strong collaboration between my fellowship director’s lab and drug delivery expert, Dr Ghandheri’s lab, I became passionate about identifying unique disease targets that could be targeted by nanotherapeutic technology to develop novel and more effective topical drug delivery systems. To this end, we published several papers assessing various targetable differences between disease and healthy sinonasal tissue, including a publication in Nanomedicine focusing on leveraging vascular dysregulation differences across these cohorts to improve drug tunability. Although my mentors were focused on optimizing systemic drug delivery, I became interested in improving topical delivery. At the end of fellowship, I characterized a novel sinonasal epithelial cell type previously only described in the Peyer’s patches of the human gut. This microfold cell has a unique apical membrane receptor known as glycoprotein 2 (GP2) receptor, which is utilized by the cell to bind and endocytose various antigens. The goal of the present proposal is to develop a targeted, nasal nanoparticle (NP) based drug delivery system that utilizes an anti-GP2 antibody conjugation to bind epithelial cell GP2 receptors and initiate endocytosis across the apical membrane. I aspire to become a national and international leader in targeted drug delivery within the upper airway and am fully committed to working with colleagues in otolaryngology, pulmonology, and drug delivery to improve outcomes for patients with CRS. From a clinical perspective, my goal is to continue to nurture a clinical practice focused on treating CRS, which, in turn, informs and inspires my translational basic science studies of sinonasal NP drug delivery. This K12 provides the critical training in advanced biochemical laboratory techniques, bioinformatics, and tenets of drug delivery necessary for comprehensively studying design and implementation of targeted drug delivery systems in upper airway disease.